Healthcare Bioscience Company - Regencell $RGC holding against raging markets
The market sentiments now is filled with uncertainty and fear, seeing large drops of more than 50% in major large market capital stock prices. (especially in the tech sector). The negative contributions are non other than the rise in inflationary and Consumer Price Index (CPI) numbers which have recorded to beat analysis estimates, sending market lower to the bearish pits.
Volatile periods calls for a reshuffling of portfolio in many investors and traders where they may opt for defensive sector equities ie. REITs, F&B, Utilities or Healthcare which has shown resilience against market turbulent.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
The stock price has seen over 300% growth since IPO was consolidating between $20-$22 before its resistance breakout in May 22” and shown a bullish pattern in recent weeks. The stock price has shown major resilience towards market volatility and could be contributed to its strong backing of the company CEO (Mr Au) whom has bought over $5 Million Dollars worth of company share in recent period and not sold any since its IPO inception.
The CEO has also demonstrated commitment towards the company by just being paid $1 Dollars annually and will receive no bonuses until the company’s market capital is reached $1 Billion Dollars. Early investors within the company (ie. directors and employees) have agreed to a stock option lockup period of 6 months after the stock option becomes vested. (lock up till 16th January 2023).
Having the full support and confidence of the company CEO and its employees, we hope to see further upside and positive news on the company, especially on treatments of ADHD, ASD & Covid19 with the company’s TCM method.
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
The market sentiments now is filled with uncertainty and fear, seeing large drops of more than 50% in major large market capital stock prices. (especially in the tech sector). The negative contributions are non other than the rise in inflationary and Consumer Price Index (CPI) numbers which have recorded to beat analysis estimates, sending market lower to the bearish pits.
Volatile periods calls for a reshuffling of portfolio in many investors and traders where they may opt for defensive sector equities ie. REITs, F&B, Utilities or Healthcare which has shown resilience against market turbulent.
Regencell Bioscience Limited’s (NASDAQ:RGC) a bioscience and healthcare company which focuses heavily on R&D and commercialization of Traditional Chinese Medicine (”TCM”) treatment specifically Attention Deficit Hyperactivity Disorder (”ADHD”) and Autism Spectrum Disorders (”ASD”), and infectious diseases affecting people’s immune system such as COVID.
The stock price has seen over 300% growth since IPO was consolidating between $20-$22 before its resistance breakout in May 22” and shown a bullish pattern in recent weeks. The stock price has shown major resilience towards market volatility and could be contributed to its strong backing of the company CEO (Mr Au) whom has bought over $5 Million Dollars worth of company share in recent period and not sold any since its IPO inception.
The CEO has also demonstrated commitment towards the company by just being paid $1 Dollars annually and will receive no bonuses until the company’s market capital is reached $1 Billion Dollars. Early investors within the company (ie. directors and employees) have agreed to a stock option lockup period of 6 months after the stock option becomes vested. (lock up till 16th January 2023).
Having the full support and confidence of the company CEO and its employees, we hope to see further upside and positive news on the company, especially on treatments of ADHD, ASD & Covid19 with the company’s TCM method.
[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]
